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Abstract 
A disease characterized by the occurrence of multiple endocrine tumors, Multiple 
Endocrine Neoplasia type 1, or MEN-1, is found to be the result of mutations in the 
MEN-1 gene.  The MEN-1 gene encodes a protein called menin, which has been puzzling 
pathologists and cell biologists for years.  The intricacy surrounding this protein has led 
to much effort in research.  Recently, menin is shown to regulate many crucial functions 
in the cell by interacting with other protein factors.  These interactions, however, are not 
well characterized, and the actual functions of menin have not been confirmed. 
Nevertheless, some recent discoveries and speculations have shed light on the function of 
menin, suggesting that it is a tumor-suppressor that prevents the onset of the MEN-1 
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1. Introduction 
First reported by various physicians in the early twentieth century, multiple 
endocrine neoplasia syndrome family consists of several subsets of disease, one of which 
is multiple endocrine neoplasia type 1, or MEN-1.  MEN-1, a disease that is estimated to 
occur in about one in 30,000 individuals, is inherited in an autosomal dominant manner 
and is caused by mutations in a gene on chromosome 11q13, the MEN-1 gene [1, 15, 38].  
It can also be caused by sporadic mutations in the same gene.  MEN-1 gene encodes a 
610-base pair protein, menin, which functions as a tumor-suppressor in the nucleus [2, 
38].  Mutation in this tumor-suppressor causes several different tumors in the endocrine 
system with a high degree of penetrance.   
The principle characterizing tumor types include parathyroid tumors, 
gastroenteropancreatic neuroendocrine tumors (GEPNETs), and pituitary tumors.  Other 
less common types of tumors are also associated with MEN-1, but their frequency of 
occurrence varies among individual cases of MEN-1 mutations [3].  These tumors may be 
malignant or benign, and they may appear together or at different times among patients in 
all age groups.  Early discovery of MEN-1 parallels that of other tumor types, but the 
diagnosis of MEN-1 is usually confirmed by genetic testing, which has become quite 
common.  Current treatments for MEN-1 also parallel those for other tumor types, 
including surgical removal of the neoplastic tissue, chemotherapy, radiotherapy 
treatment, etc.  Finding more effective treatments for this disease is currently under active 
research.   
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2. Diagnosis 
The initial manifestation of MEN-1 involves identification of three principle 
tumor types: tumors of the parathyroid, pancreatic islets, and anterior pituitary glands.  
Development of other tumors that occur less frequently in MEN-1 patients is also 
observed, including adrenocortical tumors, foregut carcinoids, facial angiofibromas, 
collagenomas, lipomas, and meningiomas [4, 16].  These tumors often cause the initial 
symptoms that lead to suspicion of MEN-1, but the specific symptoms depend on the 
developmental stage, the actual tissues involved, and the particular hormones being 
overexpressed; they usually differ between different patients, even between identical 
twins [5].  Because it is known that MEN-1 is caused by a mutation in the MEN-1 gene, 
genetic testing has been largely successful in detecting potential MEN-1 development 
prior to its onset.   
In clinical practice, the confirmation of one in three criteria leads to establishment 
of a diagnosis: the appearance of two or more of the three principle tumors in a patient, 
the appearance of one of the less-frequently-observed tumors associated with MEN-1 in a 
first-degree relative of a patient with diagnosed MEN-1 disease, and the identification of 
a MEN-1 gene mutation through genetic testing, even if the patient has not yet developed 
any clinical symptoms that are usually associated with MEN-1 disease [6].  
The chief complaint of MEN-1 is usually complications due to hormonal excess, 
but the principal cause of death is usually the progression of duodenopancreatic 
neuroendocrine cancers or intrathoracic carcinoids.  Previously, it was recommended for 
non-symptomatic individuals carrying MEN-1 mutations to begin annual biochemical 
testing as soon as they turn fifteen, in order to ensure early detection of any 
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abnormalities.  The annual testing measures gastrin, glucagon, and chromogranin A 
levels [3].   
Today, more aggressive measures are recommended to individuals with MEN-1 
gene mutation prior to the onset of the disease.  These measures are specifically designed 
for individuals with familiar MEN-1 disease, in which the affected children begin 
pituitary screening of prolactin level at age 5.  If prolactin level is elevated, an MRI is 
recommended for further screening of the pituitary area.  If normal, the pituitary 
screening is then performed annually.  At age 8, children begin annual parathyroid 
screening of calcium and PTH levels; if these levels are elevated, Sestamibi parathyroid 
scintigraphy and ultrasound are performed for further investigations of the parathyroid 
glands.  Sestamibi parathyroid scintigraphy detects the presence of parathyroid adenomas 
by using the radioactive Technetium-99m, which is absorbed at a greater rate by a hyper-
activating parathyroid gland as compared to a normal gland.  If these levels are normal, 
parathyroid screening is also performed annually for further monitoring.  At age 20, 
affected adults begin annual pancreas screening (gastrin, chromogranin A, proinsulin, 
glucagon, and CT/MRT).  If normal, annual pancreas screening is performed.  On the 
other hand, if gastrin, chromogranin A, and glucagon levels are elevated, somatostatin 
receptor scintigraphy (SRS) and endoscopic ultrasound (EUS) are performed to detect 
possible insulinoma and gastrinoma.  If elevated proinsulin is detected, fasting state in the 
patient is clinically observed.  CT/MRI can also identify abnormalities [13, 17, 18, 24].   
2.1. Parathyroid Tumors 
Parathyroid tumors are the most frequent tumor type occurring in MEN-1 
patients, typically with a penetrance of more than 95% [5, 16].  Due to these tumors, the 
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most common symptom of MEN-1 is primary hyperparathyroidism, characterized by 
enlarged, asymmetrical parathyroid glands, which occurs in about 90% of patients [3, 4].  
Other clinical signs may include hypercalcemia (polyuria, polydipsia, constipation, and 
malaise), nephrolithiasis, osteitis fibrosa cystica, and peptic ulcers.  The observed 
increase in parathyroid hormone concentration is also associated with hypercalcemia 
[13].  In some rare cases, renal lithiasis and skeletal complications of 
hyperparathyroidism may occur [19].   
2.2. Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs) 
GENPNETs are the second-most frequent tumor type occurring in MEN-1 
patients, typically with a penetrance of 30%-80% [3, 4, 27-30].  These tumors actually 
cause the highest morbidity and mortality among patients with MEN-1 disease [3].  Some 
tumors in this category that are associated in with MEN-1 include enteropancreatic 
tumor, gastrinoma, insulinoma, glucagonoma, etc.  Many of these tumors cause 
overproduction of various hormones, and testing of these hormones is utilized in annual 
screening of the progression of MEN-1 in patients as mentioned above.  Diffuse islet cell 
hyperplasia and microadenoma formation may also be formed in pancreatic tissue, which 
may easily be overlooked [19].   
In most patients, computed tomography (CT) and magnetic resonance imaging 
(MRI) may be used to detect the presence of a very large neoplasm.  However, imaging 
effectiveness and accuracy decrease as the diameter of the tumor decrease, as the number 
of tumors increases, and if the location of tumor is either outside or on the edge of the 
pancreas [19].  Endoscopic ultrasonography (EUS) has been shown to be a superb 
imaging technique for these MEN-1-associated NETs.  It has been shown that EUS can 
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detect the tumors with up to 95% specificity and 82% sensitivity.  Somatostatin receptor 
scintigraphy (SRS) is also used to detect various GENPNET tumors with 100% positive 
predictive value.  However, the specificity is relatively poor, with only about 25% 
specificity for pancreatic tumors [18, 27, 31, 32].  A rather invasive screening test called 
selective pancreatic arteriography with stimulation that measures hormonal secretion in 
the hepatic vein is shown to be the most accurate test present for detecting GENPNET 
tumors in MEN-1 patients [33].   
Pancreatic NETs in MEN-1 patients are mostly nonfunctioning or they secrete 
pancreatic polypeptides, but the most common and active MEN-1-associated NET is 
gastrinoma, which results in hypergastrinemia in these patients.  Clinical signs and 
symptoms may include epigastric pain, reflux esophagitis, and diarrhea.  Gastric acid 
hypersecretion and elevated fasting levels of serum gastrin are usually observed.  MEN-
1-associated gastrinomas have approximately 80% malignancy and are relatively small, 
which makes them difficult to be detected early [13, 19].   
Another active GENPNET in MEN-1 patients is insulinoma.  Insulinomas are 
often small and are distributed evenly across the pancreas.  Symptoms of this type of 
tumor result from neuroglycopenia, including sweating, dizziness, and syncope.  A 
diagnosis is made when these typical symptoms of hypoglycemia are observed along with 
abnormally elevated insulin and C-peptide levels during a 72-hour fast.  Insulinomas are 
sometimes localized by imaging techniques such as CT, ultrasound, MRI, or angiography 
[13, 19]. 
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Other tumors of MEN-1-associated GENPNET include glucagonoma, 
somatostatinoma, VIP-secreting tumors (VIPomas), etc.  These tumors occur very rarely, 
and signs and symptoms vary depending on the different hormones affected [13]. 
2.3. Anterior Pituitary Tumors 
Anterior pituitary tumors are the third-most frequent tumor type occurring in 
MEN-1 patients, typically with a penetrance of about 30%-50% [5, 16].  MEN-1-
associated pituitary adenomas are more frequently seen in women than in men, and they 
are also more frequently classified as macroadenomas with more aggressive behaviors 
than non-MEN-1-associated pituitary adenomas [35].  However, the prevalence of 
pituitary carcinoma is similar in pituitary adenomas in both situations [36].  It is indicated 
that in MEN-1-associated pituitary tumors, about 60% of them secrete prolactin, 25% 
secrete growth hormone, and 5% secrete adrenocorticotropic hormone (ACTH) [12, 36, 
37].  In some cases, overexpression of multiple hormones is more frequently associated 
with pituitary tumors caused by MEN-1 [12, 35].  The signs and symptoms in MEN-1 
patients depend on the actual hormones affected and the size of the tumors themselves.  
Some possible signs and symptoms include hyperprolactinemia, which may cause 
infertility in men and women, acromegaly, Cushing’s disease, visual disturbances, 
hypopituitarism, etc.  Clinical screening of pituitary tumors in MEN-1 patients include 
monitor of serum prolactin and IGF-I levels, and MRI of the pituitary gland [13].   
2.4. Other Tumors 
These less-common tumors include carcinoid tumors, adrenocortical tumors, 
lipomas, facial angiofibromas, thyroid tumors, etc.  Their effects on MEN-1 patients vary 
depending on the actual hormones affected as well as the size of the tumors. 
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3. Etiology 
The MEN-1 tumor suppressor gene was mapped to chromosome 11q13 in 1997 
[38].  This gene encodes a 610-amino acid, tumor-suppressor protein, menin, which is a 
ubiquitous nuclear protein that is thought to regulate cells via influence on pausing the 
cell cycle, which halts cellular growth and proliferation.  If this protein is non-functional, 
it is natural for the affected cell to become neoplastic, or to undergo uncontrolled growth 
and division.  The Knudson two-hit model has been proposed and has been largely 
accepted for this neoplastic transformation to occur in both alleles of the MEN-1 gene.  
The first hit, or gene mutation, is the inherited germline mutation that is present in every 
cell of the body.  The second mutation on the other allele of the same gene occurs in cells 
of the targeted tissue, which results in a complete gene knockout in these cells, leading to 
the eventual tumor formation [40].   
The loss-of-function in the MEN-1 tumor suppressor gene is thereby proposed to 
result in many tumors, including parathyroid tumors, gastrinomas, pituitary tumors, etc.  
The protein menin is found to be highly conserved in evolution from Drosophilae to mice 
to human.  To demonstrate the importance of the menin protein in cells, a murine model 
was generated with homologous recombination.  It is shown that homozygous MEN-1 
knockout mice die before birth, which suggests that menin is critical in early embryonic 
development and that it functions more than just in the endocrine tissues.  Heterozygous 
mice show symptoms very similar to humans who develop MEN-1 disease.  These mice 
begin developing neoplastic tissues and tumors I the endocrine system as early as 9 
months [39]. 
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 Even though the function of menin as a tumor-suppressor protein has been 
proposed by various research groups, the exact mechanisms of its functions have not been 
elucidated, and some of its cellular roles may even seem contradictory.  Current 
understanding of menin’s role as a tumor-suppressor will be presented in later sections of 
this paper.  
4. Treatment 
Treatment for MEN-1 patients with tumors typically resembles that for any other 
cancer patient with a similar tumor, often involving multiple medical disciplines 
including oncology, endocrine surgery, radiology, genetics, etc.  However, these standard 
cancer treatments are not as effective in MEN-1 patients as they are in non-MEN-1 
patients.  The first possible reason is that MEN-1 usually causes multiple tumors, which 
makes complete surgical removal more difficult than in traditional patients.  For example, 
in patients after undergoing surgery to remove multiple submucosal duodenal 
gastronimas, non-MEN-1 patients are cured 45% of the time, whereas MEN-1 patients 
are only cured about 15% of the time [1, 7-10].  The second reason is that metastasis of 
tumors occurs much more frequently in MEN-1 patients than in non-MEN-1 patients.  
For example, in patients with insulinomas, metastasis occurred in 50% of MEN-1 
patients, whereas it occurred in less than 10% of non-MEN-1 patients [11].  The third 
reason is that the tumors are larger and more aggressive in MEN-1 patients as compared 
to their non-MEN-1 counterparts.  For example, it is shown that secretion of pituitary 
adenomas is more abundant and more frequent in patients with MEN-1 than those with 
non-MEN-1 [12]. 
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4.1. Parathyroid Tumors 
Currently, the most definitive treatment for MEN-1 patients with parathyroid 
tumors is surgical removal of the abnormal parathyroid glands.  It is desired to preserve 
the unaffected tissue, but all four parathyroid glands are affected in many cases.  It is 
often difficult to decide, however, whether the surgery should be a total or partial 
parathyroidectomy, since the distinction between healthy and neoplastic tissue is not 
always clear; it is also difficult to determine whether the surgery will be more effective 
when performed at an early or a late stage [13].   
Partial parathyroidectomy has been associated with hypercalcemia in 40 to 60% 
of postsurgical MEN-1 patients, and with hypocalcemia in about 10 to 30% of patients in 
whom vitamin D or calcitriol treatments are required [20-23].  In MEN-1 patients who 
have undergone total parathyroidectomy with IM autotransplantation into the forearm 
muscle, the effectiveness of the transplanted tissue is observed to worsen over time, 
which explains hypocalcemia in some patients.  Hypercalcemia in other cases may either 
result from hyperactive autografts or the neoplastic residual parathyroid gland.  In a 
recent study, it is shown that the use of less tissue can improve the side effects of 
autotransplantation such as reducing the occurrence of hypercalcemia, and also 
hypoparathyroidism, which occurs through high serum calcium negative feedback [25].  
In patients with residual parathyroid tissue, it is shown that recurrent 
hyperparathyroidism in patients 5 years after surgery is about 30% to 40%, which reflects 
the MEN-1 genetic disposition in every cell in patients with MEN-1 gene mutation.  
These results also depend on the time interval these patients were followed, and also 
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whether the thymus was also removed, which may interfere with parathyroid hormone 
production due to a physiological feedback loop [26].    
4.2. Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs) 
The only possible cure at present for MEN-1-associated GEPNETs is surgery.  
However, the effectiveness of surgery remains largely controversial.  It is demonstrated 
that MEN-1 patients with gastrinoma are rarely completely cured after undergoing 
surgery, but surgical removal of the neoplastic tissue may prevent metastasis and thereby 
controls progression of tumors [7].   
Varying among individual MEN-1 cases, lymphadenectomy, 
pancreaticoduodenectomy, or even total gastrectomy may be performed [34].  Instead of 
a total gastrectomy, however, administration of proton-pump inhibitors is often effective 
enough to control acid hypersecretion that is resulted from gastrinoma.  Chronic 
administration of PPIs may cause gastric carcinoid tumors, so endoscopy is used to 
observe patients on PPIs.  The recommended treatment for insulinoma is surgical 
removal of neoplastic tissue to improve the situation in hyperinsulinemia, but sometimes 
partial pancreatectomy may be required when multiple or possible malignant tumors are 
observed.  Treptozotocin treatment may work on patients with malignant insulinoma, and 
diazoxide or octreotide may be used to treat hypoglycemia [13, 19, 33].  Most other rare 
MEN-1-associated GEPNETs require surgical removal of neoplastic tissues and 
administration of various drugs [3, 4, 13].  
4.3. Anterior Pituitary Tumors 
The recommended treatments for MEN-1-associated tumors are similar to their 
non-MEN-1 counterparts, which include medical therapy or transsphenoidal 
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adenomectomy with radiotherapy.  It is shown that MEN-1-assocaited pituitary tumors 
tend to be larger and more aggressive, so multiple surgeries may be needed to benefits the 
patients [13]. 
4.4. Other Tumors 
Surgical removal of the neoplastic tissues is usually recommended, and some 
biochemical agonists/antagonists are used to counteract hormonal effects in these tumors 
[13, 19]. 
5. Literature Review 
5.1. Current Research 
Current research focuses mainly on treating MEN-1 with improved treatment 
methods.  The present difficulty in advancing the optimal treatment methods centers on 
the lack of clinical trials, especially due to lack of the desired number of MEN-1 patients.  
It is therefore crucial to work in cooperation with research centers in other countries.  
Nevertheless, many innovative and potentially curative therapies have been developing in 
recent years.   
It has been shown that the common systemic chemotherapies are not very 
effective in treating late-stage metastasized pancreatic NETs because of their low 
proliferation rates, and many novel chemotherapy agents that target angiogenesis, 
tyrosine receptor kinase, have been showing excellent results [48].  When menin acts as 
an inductor of gene expression, the interaction between menin and MLL1 should be 
disrupted to prevent leukaemogenesis, and thienopyrimidine has been shown to act as a 
therapeutic factor [13, 49-51].   Further understanding in the biological process in MEN-1 
will lead to more effective treatments.      
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A recent publication in Cancer Research has indicated initial success in gene 
therapy in treating MEN-1 in mice.  An adenoviral serotype 5 vector (rAd5) with 
recombinant MEN-1 cDNA under a cytomegalovirus promoter control was injected into 
the pituitary tumors of some Men1+/- female mice.  It was followed by the administration 
of 5-bromo-2-deoxyuridine (BrdUrd) in water, and the progression of the tumor was 
monitored with magnetic resonance imaging (MRI) and immunohistochemical analysis 
four weeks after the treatment.  It was shown that menin expression in these treated mice 
was elevated.  The rate of BrdUrd incorporation in genes is reduced as compared to mice 
in the control group, which shows that the cell proliferation rates are reduced.  However, 
surprisingly, the menin protein upregulation is not shown to be associated with an 
increased apoptotic rate in vivo.  This may be due to reasons such as delayed testing, 
differences in oncogenic and apoptotic pathways, and the possible effects from other cells 
in the same tissue [47].  Nevertheless, this paper provided an excellent first step towards 
finding a cure for MEN-1 disease.  
The researchers in Walls et al chose to target the pituitary adenomas with rAd5 
vectors containing cDNA because pituitary adenomas are localized in one area whereas 
GEPNETs are not confined but rather spread evenly throughout an organ such as the 
pancreas.  However, GEPNETs are far more life threatening than other types of MEN-1-
associated tumors because detection of these tumors and complete surgical removal of all 
tumor mass are difficult.  It is therefore crucial to develop a technique that is possible to 
target each cancerous cell in order to eliminate the tumors.   
In the paper, the researchers targeted the pituitary adenomas with “transauricular 
and intratumoral” injections directly into the tumor mass because the vector themselves 
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lack targeting specificity.  Therefore, in the following experiment, it will be important to 
design a vector that contains targeting specificity for several reasons.  First of all, since 
the protein menin has not been understood completely, overexpression of it should be 
avoided in non-cancerous cells if possible.  Secondly, targeting specificity will contribute 
to localization of the tumor, which can aid in surgical removal of a large tumor mass.  
Thirdly, a systemic delivery rather than intratumoral injection can be screened more 
easily for immunogenicity to avoid eliciting immune responses in future clinical trials.  
Lastly, some slow-growing MEN-1 associated tumors are difficult to eliminate with 
chemotherapy, but vesicles with targeting specificity can deliver proteins and drugs to 
these cells more accurately, thereby removing the cancerous cells completely.   
In a paper by Alvarez-Erviti et al, researchers were able to engineer a vesicle 
from exosomes with targeting specificity for neurons, microglia, and oligodendrocytes to 
achieve gene knockout.  In regards to treating MEN-1, the use of the rAd5 vectors may 
be appropriate because of its benefits in targeting cancer cells as explained in Walls et al.  
However, since rAd5 vectors are foreign, using a self-derived exosome may be less 
immunogenic.  In Alvarez-Erviti et al, the researchers used exosomes produced by 
immature dendritic cells because these exosomes have not expressed T-cell activators on 
their surfaces yet to avoid immune response.  Because both types of vesicles have their 
advantages, it is therefore beneficial to engineer both of them and compare their 
effectiveness.  Subsequently, it may be possible to fuse targeting peptides for tumor cells 
to proteins expressed on vesicle membranes and then transfect these proteins with 
plasmids to the vesicles.  Finding peptides that specifically target cancer cells will be the 
most challenging part of the following experiments.  Some possible targeting peptides 
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may specifically target angiogenesis and/or telomerase activity in cancer cells to ensure 
accurate delivery of menin proteins and other potential drugs.  Finally, several engineered 
vesicles can be tested in mice to compare their effectiveness.  Since pituitary adenomas 
should be the most appropriate testing and monitoring targets, MRI can be used to 
monitor tumor progression [47, 52]. 
5.2. Known Functions of the Protein Menin 
Menin is found to function in the nucleus [2].  It has a variety of functions in the 
cell such as regulating gene transcription, cell cycle advancement, apoptotic pathways, 
DNA repairing processes, etc. [3, 55].  Menin mediates these cellular processes via 
interaction with many proteins.  One of these proteins is JunD, which is a component of 
the activator protein-1 (AP-1) complex, which in turn regulates various cellular activities 
including development, neoplastic transformation, proliferation, differentiation, and 
apoptosis [19]. 
Menin also binds many other proteins such as Smad3, NF-κB, nm 23, etc., that 
function as DNA-processing factors, DNA repair proteins, transcription factors, etc.  It 
has also been shown that menin suppresses the tumorigenic phenotype as well as 
telomerase activity in cells, which are roles consistent with its tumor-suppressing 
function [40, 41].  Another direct role of menin is seen in association with the Fanconi 
anaemia protein (FANCD2), which is part of a process that reacts to DNA damage; 
FANCD2 is also shown to be involved in the BRCA/p53 pathway that suppresses tumor 
formation in cells [45, 46].   
Surprising, menin also seems to have some contradicting roles in a cell.  Menin 
interacts with a histone methyltransferase complex, mixed lineage leukemia protein 1 
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(MLL1), and it is shown to trimethylate histone H3 lysine 4 and halt the cell cycle before 
the S phase, thereby elevating the expression of certain cyclin-dependent kinase 
inhibitors.  It is shown to be an oncogenic cofactor that functions to elevate gene 
transcription [19, 42, 43, 49]. It was thought that menin may act as a scaffold to interact 
with MLL1 and chromatin binding factor lens epithelium-derived growth factor 
(LEDGF) proteins to promote gene transcription and induce leukaemogenesis in cells, 
thereby initiating and progressing tumor formation [44, 49].  The contradicting roles of 
menin will be very interesting for future research.   
5.3. Evidence of Menin’s Tumor-Suppressing Role  
 Ever since the MEN-1 gene has been sequenced and genetic testing has been used 
as a way to confirm MEN-1 disease, various mutations have been identified in germline 
cells in patients with MEN-1, including nonsense, frameshift, missense, point mutations, 
etc.  Most of these mutations result in mutated menin expression.  The strong correlation 
between mutated menin protein and MEN-1 disease development suggests that the 
protein menin is very like to be a tumor-suppressor.  However, correlation does not 
guarantee causation.  Therefore, various research groups have tried to confirm menin’s 
role in tumor suppressing by generating researching models. 
One such model was developed by Crabtree et al.  Previously, the MEN-1 gene 
has been localized to chromosome 19 in the murine genome, and it is found to be very 
similar in structure to its ortholog in the human genome with 98% similarity and 97% 
identity.  Therefore, the researchers chose mice to construct their study model in order to 
demonstrate causality.  Initially, through homologous recombination via insertion of the 
PGK-neomycin cassette in intron 2, the researchers achieved conditional gene knockout.  
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However, these mice with two mutated MEN-1 genes died before birth.  Embryonic 
lethality due to menin mutation has also been demonstrated by other researchers 
including Bertolino et al., and most of these knockout mice died between E11.5 and 
E13.5 due to defects in liver, heart, and the nervous system.  Clinical features including 
body hemorrhages, edemas, and improper disclosure of the neural tube have been 
observed.  Furthermore, the expression of menin has been detected in many early tissues.  
All these observations indicate a crucial role of menin in embryos, which also explains its 
ubiquitous distribution in the later life stages, implying its critical functions throughout 
development in many organisms.  Mice with heterozygous gene mutation have shown 
tumor progression and distribution similar to that in human MEN-1 patients, such as the 
development of islet cells from normal to hyperplastic and finally to the formation of 
tumors.  Other cancers developed include pituitary adenoma, parathyroid adenoma, and 
adrenal cortical tumors, which are all tumors as observe in human MEN-1 patients.  
However, some rare tumors were also formed in mice that were not observed in human 
patients.  This could be due to difference between murine and human gene, or due to the 
specifically targeted intron [39, 66].  Future research can focus on comparing the 
different tumor patterns generated by silencing different introns in the MEN-1 gene.  
Even though clinical observations studied with murine models indicate menin’s essential 
role in tumor suppressing, the precise mechanism of how menin acts as a tumor 
suppressor has not been elucidated.  Several possible mechanisms have been proposed, 
but further studies will be needed to validate their precision. 
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5.4. Menin’s Interaction with the Transcription Factor JunD 
  JunD belongs to the AP-1 complex family.  AP-1, usually acting as a 
heterodimer, may be formed from different proteins including ATF (ATF2, LRF1/ATF3 
and B-ATF), Jun (c-Jun, JunB, JunD), and Fos (c-Fos, FosB, Fra-1, Fra-2), and it is 
found to interact with cell regulators such as Cyclin D1, p53, p21, p19, and p16.  The AP-
1 complex family is found to negatively control cell proliferation [41, 53, 54].   
JunD is expressed in all cell types.  It protects the cell from p53-dependent 
apoptosis, and it also negatively regulates RAS-dependent cell growth.  Menin is found to 
repress JunD-mediated gene transcription via interaction between the C-terminal 
transcription activation domain of menin and the N-terminal transcription activation 
domain of JunD, but menin is not found to interact with other members of the AP-1 
family.  Menin specifically recruits histone deacetylase (HDAC) through interaction with 
mSin3A.  The general transcriptional corepressor mSin3A binds to HDAC via the 
HDAC-interaction domain.  Having recruited HDAC, menin can now direct histone 
modification on various genes whose transcription is activated by JunD, thereby 
suppressing JunD-mediated gene transcription [63, 64]. 
Menin suppressing JunD expression was first discovered by Agarwal et al. in 
1999.  In this study, JunD was fused to a heterologous DNA-binding domain, Gal4, and 
was found to activate its transcription.  Initially, the researchers did not use an AP-1 
binding site to avoid issues surrounding competition from nonspecific binding of other 
AP-1 transcription factors, which would affect the accuracy of signal detection.  They 
found that if the testing cells (NTera2 or 293wt) were transfected with the fused 
transcription factor, Gal4DBD-JD1, a Gal4-responsive reporter, pFR, and the menin 
	   18 
expression construct plasmid, transcription of the fused gene is repressed.  If the testing 
cells were transfected with a plasmid with mutant menin, however, JunD-mediated gene 
expression level was similar to that of cells without menin expression.  Perplexed by the 
results, the researchers then used a JunD-specific TRE site to again test the menin-JunD 
interaction.  They transfected the testing cells with a JunD expression plasmid, a TRE 
reporter plasmid pAP1, and different (both normal and mutated form) menin expression 
constructs to monitor gene expression levels.  Not surprisingly, JunD transcription was 
again repressed by menin expression [41].   
The researchers were perplexed because it seems contradictory to menin’s tumor 
suppressor role that menin suppresses JunD, which is a cell growth inhibitor itself.  
However, experiments in which the interaction between JunD and menin is disrupted 
have resulted in increased cellular proliferation.  Moreover, when JunD exists in a menin-
null environment, it appears to promote cellular growth.  Its function to elevate gene 
expression seems to be reversed by its binding to menin.  It is thereby proposed that JunD 
may be able to act as an inhibitor of cell proliferation only when it is bound to menin, and 
in normal cellular environment, JunD usually forms a complex with menin.  Therefore, 
when menin protein is mutated in MEN-1 patients, it is likely that the association 
between menin and JunD is disrupted, which results in failure to inhibit cellular growth 
and eventual tumor formation [55, 65].   
Even though these proposed cellular activities, if correct, would be able to explain 
menin’s tumor-suppressing function, it is nevertheless puzzling as to why menin 
“suppresses” JunD activity as shown in the original study.  In other words, binding to 
menin should not be suppressing JunD activity but rather reversing its function 
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completely.  It is likely that this confusion is the result of in vitro study since an actual 
genetic environment cannot be replicated.  One possible explanation is that when the 
menin-JunD complex is formed, the original genes could not be expressed, which leads to 
inhibition of cellular growth.  In other words, menin destabilizes menin binding to the 
activating sequence, which inhibits cellular growth because the required growth genes are 
not transcribed as a result of the binding.  This mechanism seems to be the most likely 
explanation to menin’s tumor-suppressing role.  Unfortunately, this finding also poses a 
problem in uncertainty with treatment.  If JunD is mutated and cannot form a functional 
complex with menin, it is likely that such disruption also causes phenotypes similar to 
those of MEN-1 disease, adding the possible inaccuracy in genetic testing.  Therefore, 
finding a right cure for patients will be very difficult since understanding pathology will 
be challenging.  However, the discovery of an enormous variety of cellular malfunctions 
will likely stimulate the development of personalized medicine. 
5.5. Menin’s Interaction with TGF-β  
 Transforming growth factor-beta (TGF-β) is a cytokine that mediates various 
functions including cell growth regulation, development, apoptosis, etc., and it binds to 
its receptors on the cellular surface.  The TGF-β receptor is composed of TGF-β types 1 
and type 2 receptors, and they both contain a serine/threonine kinase domain.  Once TGF-
β binds to and stimulates the receptors, the type 2 receptor phosphorylates a 
glycine/serine-rich domain on the type 1 receptor, and the type 1 receptor in turn 
phosphorylates a signal transducing complex, the receptor-specific Smads (R-Smads, or 
Smad2 and Smad3).  The phosphorylated signal transducers then form a complex with 
Smad4, which belongs to the common-partner Smads (Co-Smads) family.  Subsequently, 
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the complex is translocated into the nucleus, and Smad3 becomes associated with menin.  
Menin stabilizes the complex, and the complex binds to certain genes to either elevate or 
repress their expressions.  Mutated menin protein is found to block TGF-β signaling, and 
the blockage thereby disrupts cellular balance, which eventually leads to cellular defects 
and tumor formation.  Once the mechanism is elucidated, it may serve as an explanation 
for tumorigenesis resulting from defective menin proteins.  Interestingly, it is found that 
cancer cells can lose tumor-suppressing responses of TGF-β, and, through mechanisms 
unknown, can avoid or even utilize TGF-β cascade to its advantage in evading the 
immune system, promoting cancer growth, and metastasis [13, 55-57, 60].  If cancer cells 
can disrupt the function of TGF-β, however, it is possible that tumorigenesis in some 
MEN-1 related tumor cells may not solely be the result of defective menin proteins.  This 
problem in turn puts forth yet another obstacle in curing MEN-1-related disease through 
approaches such as gene therapy.   
5.6. Menin’s Function as a Telomerase Suppressor  
 The expression of telomerase, a reverse transcriptase that elongates telomeres, is 
down-regulated in most somatic cells.  Its high expression in stems cells and many cancer 
cells is associated with cellular longevity.  Telomerase contains a protein, human 
telomerase reverse transcriptase (hTERT), and an RNA, hTR, and the latter contains a 
template for synthesizing repeated nucleotides to be added to the ends of chromosomes to 
avoid deletion of chromosomal ends.  Shortening of linear chromosomes is observed in 
somatic cells, and it is thought to be associated with cell aging [74, 75].  In various 
studies, it has been proposed that the hTERT gene expression may be one event that is 
extremely important to cancer initiation [76].  However, this gene is suggested to be 
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under strict negative control in most of the somatic cells, which in turn suppresses the 
expression of telomerase [74].  Recent research has indicated that decreased cell 
proliferation rates and apoptotic cell death in cancer tissues have been observed with 
down-regulation of the hTERT protein [77].  Therefore, it is crucial to further study the 
hTERT gene as well as its negative suppressor in most somatic cells.   
 Several tumor suppressors and oncogene pathways have been associated with 
negatively regulating the hTERT gene expression.  Among them is the MEN-1 pathway.  
In study, menin is observed to associate with the promoter of the hTERT gene through an 
unknown mediator, with JunD and NF-κB as possible candidates.  It is also observed that 
the loss of MEN-1 contributes to cells evading the senescence pathway, and the escape 
from which specifically helps them avoid cell deterioration over time [68].  These 
observations are consistent with menin’s role as a tumor suppressor.       
5.7. Menin’s Contradicting Roles 
 In various studies, menin has been found to modulate epigenetic control with 
chromatin modification.  Menin associates with the N-terminal 44 amino acids of the 
mixed lineage leukemia proteins, MLL1 and MLL2, which together form the histone 
lysine methyltransferase complexes.  These complexes trimethylate histone H3 at lysine 4 
(H3K4) to upregulate gene transcription at various loci including the p18ink4c, p27kip1, 
and Hoxa9.  The exact succeeding cellular cascades remain to be deciphered.  
In order to analyze the menin-dependent H3K4 trimethylation and gene 
expressions in pancreatic islet endocrine cells globally, these researchers utilized 
pancreatic islet-like endocrine cells (PILECs) developed from both wild-type and menin-
null murine embryonic stem cells (mESCs).  In menin-null mESCs, the level of 
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H3K4me3 was significantly reduced, which resulted in reduction in gene expression at 
the DLK1-MEG3 region and four homeobox (HOX) loci.  The MEG3 gene was found to 
act as a tumor suppressor, and it also produces a noncoding RNA, which could possibly 
contribute to its tumor-suppressing function.  Silencing of genes at the DLK1-MEG3 
region has been observed in various kinds of adenomas.  It has also been shown that 
knockout of Meg3 leads to embryonic lethality.  Interestingly, mutations in many early 
developmental factors are observed in tumors, and it is indeed very possible that tumor’s 
self-renewal properties are somehow related to these mutations.  HOX gene expression 
regulates cellular differentiation and identity.  The HOX gene family, consisting of 39 
HOX genes, is found to be affected differently in tumors.  Some of them are up-regulated 
in tumors, whereas other are down-regulated.  Deregulation of these genes is associated 
with parathyroid tumors, with specifically down-regulation of four loci.  In short, 
decreased gene expression at these loci has been associated with pituitary adenomas and 
parathyroid tumors, which in turn suggests that menin-dependent H3K4me3 may be able 
to suppress the formation and development of certain tumors.  These findings are 
consistent with menin’s role as a tumor suppressor.    
However, it has also been found that menin’s association with other proteins may 
not always be beneficial to cells.  The association between menin and MLL may be able 
to cause cancer in MLL-associated leukemia cells.  Many translocations of the MLL1 
gene have been found to cause acute lymphoid and myeloid leukemias, along with 
elevating the expression of several HOX genes including HOXA7, HOXA9, and MEIS1.  
Elevated expression of HOX genes is associated with leukaemogenesis.  In cells without 
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menin, these genes are found to be repressed, which prevents initiation of leukemia [44, 
49, 67, 69-73].   
The contradictory roles of menin are very puzzling.  This pro-oncogenic function 
of menin is a very recent discovery, so further research is needed to explain this 
peculiarity.  One possible explanation to this phenomenon is that the level of menin 
protein is precisely balanced in cells, and the overexpression of it is not appropriate.  This 
inappropriateness is observed more prominently in the blood and bone marrow cells.  
Even though introducing menin expression in Men-1+/- female mice have resulted in a 
favorable outcome—cell proliferation rate was reduced, the injection of treatment vectors 
was only local.  Therefore, any other possible, menin-related effects in different tissues 
would be disguised.  If this explanation is correct, the development of gene therapy will 
again be hindered.    
6. Discussion 
 The nuclear protein menin mediates various cellular activities including apoptosis, 
cell development, DNA repairing, etc.  These crucial cell functions have been studied in 
depth, and the tumor-suppressing role of menin has been specifically investigated by 
various research groups.  It is found that menin interacts with various protein factors to 
carry out its functions, and JunD, TGF-β, and MLL proteins are among the most-studied 
protein factors.  Menin is also found to repress the expression the gene that encodes for a 
component of the telomerase, the hTERT protein.  Through many mechanisms whose 
exact cellular cascades are unknown, menin suppresses tumor formation.  However, it has 
also been found that menin also interacts with MLL proteins to initiate leukemia in cells.  
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Further investigation into this phenomenon will be required to fully understand menin’s 
role in cells. 
 Most of the proposed menin-induced mechanisms are not completely understood.  
Further studies should be carried out to establish a causative relationship between menin 
and its repression of the hTERT gene.  A time course of menin mutation can be simulated 
in cells with menin expression.  As the MEN-1 mRNA is gradually targeted and silenced 
with varying amounts of siRNAs, the expression of the hTERT gene can be monitored 
with RT-PCR.  The hTERT protein can also be monitored with western blot.  As the 
amount of MEN-1 mRNA decreases, expression of the hTERT gene should be observed 
to increase.  The unknown mediator that binds to the hTERT gene promoter can be 
elucidated once a causative relationship between menin and this downstream gene has 
been established.  If menin is found to repress the hTERT gene transcription, mutation of 
the genes that encode for various protein factors can be silenced with siRNAs, and these 
cells with full menin function can be analyzed for elevated hTERT gene expression.   
 Further understanding of menin’s function in promoting leukemia will be difficult 
to achieve.  One possible direction is to develop murine models with Men+/- mice, and 
inject Men-1 containing expression vectors without targeting specificity into various 
tissues including the blood, muscle, and brain cortex.  A systemic upregulation of menin 
can be tested in cell samples, especially in blood cells and the bone marrow.  Once 
upregulation of menin is achieved, these mice can be analyzed for development of 
leukemia.  Chance events can be discarded with statistical analyses.  If more mice 
developed leukemia than merely chance events, blood cells and bone marrow can then be 
tested for MEN-1 overexpression with RT-PCR.  If overexpression is observed, a 
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causative relationship can again be investigated with administration of non-specific 
vesicles with siRNA to silence the MEN-1 gene in mice with leukemia.  If progression of 
leukemia is observed to be stopped or even be slowed down, a causative relationship can 
be confirmed, and further investigation of the menin-induced leukaemogenesis pathway 
can be carried out. 
7. Case Study 
Chief Complaint 
Jose Gomez is a 35 years-old, Latino male. He presents to the emergency room by 
private vehicle at 3 am, complaining of severe flank pain. 
History of Present Illness 
Jose’s vital signs, as recorded by the nurse, are as follows: 
P 100 R 12     BP 118/75 T 38°C/100.4°F       O2 98% 
Jose complains of severe right-sided flank pain with sudden onset that goes away 
abruptly. The pain has been coming and going for several hours, which started late last 
night. He describes the pain to be “stabbing.” On a scale of 10, he rates the pain to be 10. 
He also describes the pain to be radiating to the groin area, with urgent, painful urination. 
Jose notices pink urine occasionally. Jose states that he was quite frightened when he 
started experiencing the symptoms, but he decided to come to the emergency room only 
when the pain became unbearable. Jose presents with a low fever. He has tried sitting and 
lying down to alleviate his symptoms, but neither of them helped. Walking does not make 
the symptoms worse either.  
Jose has been experiencing nonspecific symptoms of generalized fatigue and 
weakness in the past few days and has used Motrin for symptomatic relief. He thinks the 
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medicine helped somewhat but also thinks that these symptoms could be due to him 
partying too hard in Mexico in this last week or so. He has also been feeling a little 
“stuffed.” He thinks he may have caught flu, but he never bothered with it. Jose traveled 
there a week ago and just returned yesterday afternoon. He admits to heavy drinking, 
usage of marijuana, and having had several unprotected sexual encounters when he was 
in Mexico. He also described a fight that took place in a bar there. He was hit in the head, 
and it made him unconscious for several seconds. Jose didn’t go see a doctor there 
because he was afraid of getting into trouble. He thinks the fatigue and weakness may be 
caused by him getting hit in the head too. He has hoped for the symptoms to go away 
once he comes back to the U.S. to recover from his crazy partying down in Mexico. 
Past Medical, Social, and Family History 
Jose is a construction worker and has only been given insurance by his company 
quite recently. He has no known allergies but suffers from depression and asthma. Jose is 
currently on Celexa for depression and uses albuterol for occasional asthma attacks. He 
says that his depression has been alleviated since he was put on the medication. Jose 
states that even without the depression component, he is introverted and does not like to 
interact with others on a daily basis, but he does not refuse drinking with others in bars. 
He also loves drinking at home. He says that his alcohol consumption varies, depending 
on his mood, but he definitely drank much more when his depression attacked him before 
he was put on the medication. He does not smoke, and he has not had sexual activity in 
years until recently. Amongst his drinking habits, bad relationship outcomes, and 
depression attacks, Jose says that he has never had suicidal or homicidal intentions and 
that he is secretly proud of himself for this. 
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Even though he is a hard worker, Jose does not have many friends and was born 
the only child. His father died from pancreatic cancer at 36 years old, and his mother, 
who drove him to the hospital, has asthma and diabetes.  
Jose’s mother states that she thinks Jose has “sugar problems” because he gets 
hungry easily. If a meal is missed or delayed, he experiences shaking, pounding 
heartbeat, and sweating. These symptoms appeared about half a year ago. Jose believes 
that he has these symptoms only because he works too hard, and his lack of insurance 
also prevented him from seeing doctors very often, so the problem was never addressed 
before now.   
Review of Systems [86, 88, 89] 
Constitutional: Unexplained gradual weight loss and fatigue in the past few 
months. Denies night sweats or sleeping pattern change. 
Worsened generalized fatigue and weakness in the past few 
days.  
ENT: Denies tinnitus, hearing loss, or discharge in ears. Runny 
nose. Denies nosebleeds. Occasional sinus pain in the past 
few days. Sore throat starting yesterday. 
Cardiovascular: Denies any chest pain, shortness of breath, or palpitations.  
Respiratory: Dry cough in the past few days.  
Gastrointestinal: Denies any nausea, vomiting, diarrhea, constipation, or 
abdominal pain.  
Genitourinary: Denies incontinence or abnormal sexual function.  
Musculoskeletal: Denies any joint pain or swelling. 
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Integumentary/breast: Denies itch/rash, lesions or wounds. Milky breast discharge 
a week ago. Denies breast pain, soreness, or lumps. 
Neurological: Denies numbness, tingling, paresthesias, seizures or faints. 
Occasional headache after the brawl. Hitting in the head 
resulted in him losing conscious five days ago. Normal 
speech. Denies unexplained falls, visual change, or eye 
pains.  
Psychiatric: Depression. Denies change in work performance or 
personality.  
Endocrine: Denies polydipsia, polyphagia. Denies intolerance to 
heat/cold.  
Hematologic/lymphatic: Denies history of blood transfusion, anemia, purpura, easy 
bruisability, or excessive bleeding. 
Allergic/immunologic: Asthma.  
Physical Examination [86, 89, 90]  
General: The patient is in mild distress but is alert and cooperative. 
He appears underweight. 
Head: Normocephalic. No pain on palpitation. 
Eyes: Pupils are equal, round, and reactive to light, bilaterally. 
Extraocular movements intact. Fundi normal. Vision is 
grossly intact. The sclerae are anicteric. 
Ears: The auditory canals are clear; the tympanic membranes are 
clear without infection or fluid. Hearing grossly intact. 
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Throat: Throat appears erythematous. No swelling, exudate, or 
lesions. Oral cavity appears normal. Teeth and gingiva in 
good general conditions. 
Neck: Supple, no jugular venous distention. 
Back: Normal posture. No scoliosis or spinal deformity. Positive 
costovertebral angle tenderness on palpation. 
Thyroid: No palpable nodules or tenderness. 
Heart: Normal S1 and S2. No S3, S4 or murmurs. Slightly faster 
rate but normal rhythm. Capillary refill in less than 2 
seconds. No carotid bruits. Peripheral pulses 2+. 
Lungs: Clear to auscultation bilaterally. 
Abdomen: Soft, nontender, nondistended, positive bowel sounds. No 
hernias are present. No organomegaly. 
Extremities: Negative for cyanosis, clubbing or edema. They are warm 
to touch.  
Skin: Negative for dryness or diaphoresis. Normal color. No 
lumps/bumps/masses. 
Genitourinary:  Testicles nontender descended bilaterally. No discharge 
from urethra. No penile or scrotal lesions or erythema. 
Neurological:  CN II-XII intact. Strength 5/5 and sensation symmetric and 
intact throughout. Reflexes 2+ throughout.  Cerebellar 
testing normal. No tremors. Negative Rhomberg Test. 
Normal gait. 
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Psychological: Mental examination normal. Oriented to person, place, and 
time. No hallucinations or abnormal behaviors observed. 
Medications/allergies: Celexa and prn albuterol. NKA. 
Laboratory Results [85, 87] 
Complete Blood Count 
RBC count    5.20 million cells/µL (4.20-5.90 million cells/µL)  
WBC count    8,000 cells/µL (4,000-11,000 cells/µL) 
Hematocrit    45% (40.0-54.0%) 
Hemoglobin    16.5 g/dL (13.5-18.0 g/dL) 
MCV     87 fL (77-103 fL) 
MCH     31.7 pg (27.0-32.0 pg) 
MCHC    34.7% (32.0-36.7%) 
Platelet count    301,000/mL (150,000-450,000/mL) 
RBC distribution width  12.3 (11.5-14.5) 
Neutrophil    3.5 thou cells/µL (2.0-8.0 thou cells/µL) 
Lymphocyte    0.7 thou cells/µL (0.6-5.5 thou cells/µL) 
Monocyte    0.50 thou cells/µL (0.24-0.88 thou cells/µL) 
Eosinophil    0.04 thou cells/µL (0.00-0.54 thou cells/µL) 
Basophil    0.04 thou cells/µL (0.00-0.06 thou cells/µL) 
Immature granulocyte   0.00 thou cells/µL (0.00-0.04 thou cells/µL) 
Neutrophil %    60.0% (50.0-80.0%) 
Lymphocyte %   15.3% (15.0-50.0%) 
Monocyte %    6.7% (1.0-11.0%) 
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Eosinophil %    0.2% (0.0-7.0%) 
Basophil %    1.8% (0.0-2.0%) 
Immature granulocyte %  0.0% (0.0-0.5%)    
 
Basic Metabolic Panel 
Serum BUN    18 mg/dL (8-29 mg/dL) 
BUN/Creatinine Ratio  16.4:1 (10-20:1) 
Calcium    12.1 mg/dL (8.4-10.2 mg/dL) 
Chloride    99 mEq/L (96-108 mEq/L) 
Carbon Dioxide   25 mEq/L (22-29 mEq/L) 
Creatinine    1.1 mEq/L (0.5-1.2 mEq/L) 
Glucose    49 mg/dL (70-136 mg/dL) 
Potassium    3.8 mEq/L (3.3-5.1 mEq/L) 
Sodium    142 mEq/L (133-145 mEq/L) 
GFR estimated   92 mL/min/1.73 m2 (>59 mL/min/1.73 m2) 
 
Other Electrolytes 
Phosphorus    1.7 mg/dL (2.6-4.5 mg/dL) 
Ionized Calcium   7.0 mg/dL (4.3-5.2 mg/dL)  
 
Liver Panel 
Alkaline Phosphatase   162 IU/L (39-117 IU/L) 
Alanine Transaminase   21 IU/L (4-40 IU/L) 
	   32 
Aspartate Aminotransferase  25 IU/L (4-37 IU/L) 
Direct Bilirubin   0.0 mg/dL (0.0-0.3 mg/dL) 
Indirect Bilirubin   0.0 mg/dL (0.0-0.7 mg/dL) 
Albumin    3.6 g/dL (3.2-5.2 g/dL) 
Total Protein    6.0 g/dL (5.9-8.4 g/dL) 
Gamma-Glutamyl Transferase 24 IU/L (7-51 IU/L) 
Lactate Dehydrogenase  101 U/L (81-216 U/L) 
Prothrombin Time   13.0 s (12.3-15.4 s) 
 
Hormones 
Parathyroid hormone   75 pg/mL (10-55 pg/mL) 
Prolactin    220 ng/mL (4.0-15.2 ng/mL) 
Growth Hormone   5 ng/mL (< 10.1 ng/mL)     
Calcitonin    9.7 pg/mL (<10 pg/mL)  
PTH-rp    15 pg/mL (14-27 pg/mL) 
 
Insulin and Related 
Insulin     11.5 µU/mL (< 6 µU/mL) 
C-Peptide     3.2 ng/mL (< 2 ng/mL) 
Proinsulin    41% (< 25%) 
Sulfonylurea Drug Screen  Negative 
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HIV STAT (Rapid HIV) 
HIV 1/2    Negative 
 
Urinalysis Complete 
Amorphous Phosphates  Negative 
Amorphous Urates   Negative 
Appearance    Clear 
Calcium Bicarbonate Crystal  Negative 
Calcium Oxalate Crystal  Positive 
Coarse Granular Casts  Negative 
Epithelial Cell Cast   Negative 
Fine Granular Casts   Negative 
Hyaline Casts    Negative 
WBC Esterase    Negative 
Red Cell Cast    Negative 
Red Cell Clumps   Positive 
Renal Epithelial Cells   Negative 
Spermatozoa    Negative 
Specific Gravity   1.006 (1.003-1.026) 
Sulfonamide Crystals    Negative 
Trichomonas Sp.   Negative 
Triple Phosphate Crystal  Negative 
Bacteria    Negative 
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Urobilinogen    Normal 
Occult Blood, Urine   Positive 
Bile     Negative 
Color     Pink 
Uric Acid Crystals   Negative 
Epithelial Cells   Negative 
Glucose    Negative 
Ketone     Negative 
Mucus     Negative 
Nitrite     Negative 
pH, Urine    5.3 (4.5-7.2) 
Protein     Negative 
Red Cells    10 cells/HPF (0-3 cells/HPF) 
White Cells    Negative 
Waxy Casts    Negative 
White Cell Cast   Negative 
White Cell Clumps   Negative 
Yeast Cells    Negative 
 
Calcium 24 HR Urine 
Calcium, 24HR Urine   450 mg/day (100-300 mg/day) 
24HR Total Urine Volume  2300 mL (1000-2500 mL) 
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Radiology 
Figure 1. Noncontrast Spiral Computed Tomography (CT) Scan [78] 
 
 
Figure 2. Brain Computed Tomography (CT) Scan [79] 
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Figure 3. Pituitary Magnetic Resonance Imaging (MRI) [80] 
 
 
Figure 4. Technetium-99m Sestamibi Scan [81] 
 
	   37 
Figure 5. Abdominal Computed Tomography (CT) Scan [82] 
 
 
Figure 6. Pancreatic Ultrasonogram [83] 
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Figure 7. Electrocardiogram (EKG) [84] 
 
Differential Diagnosis 
Flank pain:    Nephrolithiasis 
Hyperparathyroidism 







Obstruction in the GU system 
Blood clots 
Nipple discharge:   Hyperprolactinemia 
Cocaine 
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Anterior pituitary tumor 








Chronic kidney disease 
Spinal cord injury or tumors 
Herbal supplements 


















Jose is clinically diagnosed with multiple endocrine neoplasia type 1 (MEN1) 
with parathyroid gland tumor, lactotroph microadenoma, and insulinoma. He is admitted 
to the hospital.  
Treatment Plan [86] 
1. MEN1 
- Jose will be subjected to genetic testing for mutation in the Men1 gene on 11q13. 
- Jose will be informed of the diagnosis and prognosis of the disease. His lack of social 
interactions with others will be addressed, and options such as Multiple Endocrine 
Neoplasia Support Group and psychotherapy will be suggested that aim to help him go 
through the treatment process.  
- His family members will be advised to undergo genetic testing for Men1 gene mutation 
and start periodical screening tests if possible. 
2. Nephrolithiasis 
- CT scan shows the stone to be around 1 cm in diameter and located in the kidney. Jose 
has stable vital signs, is afebrile without elevated WBC, and has no obstructive symptoms 
on urinalysis. He will be subjected to shock wave lithotripsy and monitored for future 
obstructive symptoms.  
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- IV fluids and pain control when necessary to help passage of stone. 
- Nephrolithiasis is likely caused by hypercalcemia, which is likely caused by parathyroid 
gland tumor. Jose will be subjected to total parathyroidectomy with autotransplantation to 
avoid recurrent neck surgery.  
- After surgery, periodic follow-up with serum calcium determinations will be performed 
to watch for recurrences. 
3. Insulinoma 
- An intraoperative ultrasound and/or selective arterial calcium stimulation test with 
hepatic venous sampling will be ordered to precisely locate the tumor and to examine 
metastases and lesions. The tumor will be subjected to different operations depending on 
its specific location.  
- Surgical removal of neoplastic tissue is the preferred treatment. If tumor is located to 
the right of the superior mesenteric vein, it will be removed directly. If it is in the tail of 
the pancreas, laparascopic distal pancreatectomy will be recommended to preserve 
pancreas function. If it is located close to the bile ducts or embedded deeply in the head 
or body of the pancreas, pancreaticoduodenectomy will be performed.  
- After surgery, plasma glucose level will be monitored. If it exceeds 300 mg/dL, small 
subcutaneous doses of insulin every 3-6 hours will be given. 
- If Jose is not fit for surgery or if tumor resection is unsuccessful, a divided dose of up to 
1200 mg/day of diazoxide will be given, and more frequent meals will be recommended 
to manage hypoglycemia. 
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- Screen for gastrinoma by measuring fasting serum gastrin level with the upper limit of 
normal being 110 pg/mL. Other stimulations studies, spiral CT, MRI, and endoscopic 
ultrasound can be ordered if gastrinoma is suspected. 
- If metastasis is noted, chemotherapy and other interventional treatments will be 
considered. 
- Long-term follow-up is necessary for monitoring recurrences and/or metastases. He will 
undergo history and physical examination with tumor markers every 6 to 12 months for 
the first three years. 
4. Prolactinoma 
- An initial 0.25 mg dose of cabergoline will be given twice weekly at bedtime.  
- After one month of therapy, Jose will be evaluated for side effects, and his serum 
prolactin levels will be tested. If the serum prolactin concentration <= 20 ng/mL and no 
side effects have occurred, the initial dose will be continued. If no side effects are 
observed but the serum prolactin concentration is still elevated, titrate cabergoline until 
prolactin is normal.  
- If cabergoline is not well tolerated and/or does not lower the serum prolactin 
concentration effectively, a 1.25 mg dose of bromocriptine will be administered at 
bedtime everyday for one week, and its frequency will be increased to twice a day in the 
morning and at bedtime afterwards.  
- If the aforementioned treatments are not effective, Jose will be screened for other 
pituitary tumors such as somatotroph adenomas and corticotroph adenomas by retesting 
growth hormone levels in the blood and by watching for signs of Cushing’s syndrome 
development, respectively. If not, other nonfunctioning adenomas such as gonadotroph 
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adenomas and thyrotroph adenomas will be suspected. Once confirmed, each of these 
adenomas will be treated accordingly. 
- If none of the above options worked, transsphenoidal hypophysectomy will be 
performed to remove the pituitary tumor. 
5. Possible head trauma with loss of unconsciousness 
- Jose is currently asymptomatic without warning signs. No acute intracranial bleeding on 
scans. He will be monitored outpatient and given ER precautions. 
6. Asthma 
- Jose’s asthma is mild, and he states that he does well on PRN albuterol. This treatment 
will be continued. 
- Asthma control will be assessed over 1 week on the basis of clinical and functional 
respiratory events, and further follow-ups will be scheduled and treatment altered 
depending on the assessment. 
7. Depression 
- Jose states that he copes well with Celexa, so treatment will be continued. 
- Outpatient follow-up after one month. Medications will be reevaluated for drug-drug or 
drug-disease state interactions and for efficacy.  
8. Substance usage 
- Jose will be advised against further substance usage, especially regarding the 
aforementioned marijuana and alcohol. Seeking professional help and support groups 
against substance abuse will be recommended. 
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